AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9067278 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous mutation with moderate alcohol intake
Number of subjects: 202
Study 9067278 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous normal genotype with 1 or more drinks/day
Number of subjects: 202
Study 7933504 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine suppository (0.4 mg) preoperative administration (group A1)
Number of subjects: 57
Study 7933504 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine suppository (0.4 mg) postoperative administration (group A2)
Number of subjects: 57
Study 7933504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 0.1 mg of buprenorphine during surgery and postoperative administration of buprenorphine suppository (group A3)
Number of subjects: 57
Study 7933504 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 57
Study 3286537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (2 days)
Number of subjects: 965
Study 3286537 — intervention group
Group type: COMPARATOR
Intervention: Cephazolin (5 days)
Number of subjects: 965
Study 30180186 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mobile health and behavioral intervention to enhance the capacity of ORWs
Number of subjects: 60
Study 30180186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools and training for ORWs
Number of subjects: 60
Study 30180186 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation through periodic feedback
Number of subjects: 60
Study 28169080 — intervention group
Group type: EXPERIMENTAL
Intervention: music group (n=60) receiving their favorite songs
Number of subjects: 240
Study 28169080 — intervention group
Group type: EXPERIMENTAL
Intervention: massage group (n=60) receiving Swedish massage
Number of subjects: 240
Study 28169080 — intervention group
Group type: EXPERIMENTAL
Intervention: music-plus-massage group (n=60) receiving a combination of their favorite songs and Swedish massage
Number of subjects: 240
Study 28169080 — intervention group
Group type: COMPARATOR
Intervention: control (n=60) receiving the conventional primary care
Number of subjects: 240
Study 25919687 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 'VL' TMS
Number of subjects: 30
Study 25919687 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 30
Study 23522308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy-guided percutaneous tracheostomy
Number of subjects: 51
Study 23522308 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 51
Study 21909151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Pethidine 7.5mg
Number of subjects: 50
Study 21909151 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine + Saline
Number of subjects: 50
Study 19393768 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA administration with educational module
Number of subjects: 190
Study 19393768 — intervention group
Group type: COMPARATOR
Intervention: Initial explanation and baseline PPA administration
Number of subjects: 190
Study 16905783 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug regimen (Zidovudine/lamivudine plus efavirenz)
Number of subjects: 765
Study 16905783 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (Zidovudine/lamivudine/abacavir plus efavirenz)
Number of subjects: 765
Study 16905783 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug regimen
Number of subjects: 765
Study 16905783 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen
Number of subjects: 765
Study 15592270 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel (37.5 mg metronidazole per dose), once nightly for 5 nights
Number of subjects: 151
Study 15592270 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg plus nystatin 100,000 U ovules, once nightly for 5 nights
Number of subjects: 151
Study 11485952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate at a dose of 200 microg/day
Number of subjects: 2324
Study 11485952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate at doses of 100-250 microg/day
Number of subjects: 2324
Study 11485952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate at a dose of around 500 microg/day
Number of subjects: 2324
Study 9441148 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced labor (artificial rupture of membranes and oxytocin infusion)
Number of subjects: 400
Study 9441148 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labor
Number of subjects: 400
Study 9441148 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced labor
Number of subjects: 400
Study 7964952 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug regimen (etoposide, thioguanine, dexamethasone, daunorubicin, and cytarabine)
Number of subjects: 591
Study 7964952 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (cytarabine and daunorubicin, 7 + 3)
Number of subjects: 591
Study 7964952 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 591
Study 7964952 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy consolidation
Number of subjects: 591
Study 7964952 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 591
Study 2444802 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective antagonist)
Number of subjects: 14
Study 2444802 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (combined alpha/beta-receptor blockade)
Number of subjects: 14
Study 2444802 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Labetalol and Metoprolol
Number of subjects: 14
Study 28945936 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Glucose Monitoring System™
Number of subjects: 465
Study 27732947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial patients
Number of subjects: 867
Study 27732947 — intervention group
Group type: COMPARATOR
Intervention: Patients treated off-trial
Number of subjects: 867
Study 25539791 — intervention group
Group type: EXPERIMENTAL
Intervention: LY40 mg BID
Number of subjects: 1013
Study 25539791 — intervention group
Group type: EXPERIMENTAL
Intervention: LY80 mg BID
Number of subjects: 1013
Study 25539791 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS) 2 mg BID
Number of subjects: 1013
Study 25539791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013
Study 22277604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Prototyping (RP) method
Number of subjects: 10
Study 22277604 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 10
Study 20409331 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Methylprednisolone + 10 mg Lidocaine
Number of subjects: 120
Study 20409331 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Methylprednisolone + 10 mg Lidocaine
Number of subjects: 120
Study 20409331 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + 10 mg Lidocaine (placebo)
Number of subjects: 120
Study 18455517 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day vitamin C
Number of subjects: 396
Study 18455517 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin E
Number of subjects: 396
Study 18455517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 16155267 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (21% of energy as protein)
Number of subjects: 20
Study 16155267 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (9% of energy as protein)
Number of subjects: 20
Study 12717099 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (400 mg) administered orally just after admission (60 min before reperfusion)
Number of subjects: 38
Study 12717099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no allopurinol treatment)
Number of subjects: 38
Study 12717099 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol treatment group
Number of subjects: 38
Study 12717099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 10961032 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM)
Number of subjects: 568
Study 10961032 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 568
Study 9459673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (15 sessions)
Number of subjects: 27
Study 9459673 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 27
Study 8333258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid viscous eye drops 1% given twice daily
Number of subjects: 0
Study 8333258 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol eye drops 0.5% given 6 times daily
Number of subjects: 0
Study 3511401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage trihexyphenidyl (30 mg)
Number of subjects: 31
Study 31600365 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 507
Study 30194737 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program only
Number of subjects: 81
Study 30194737 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program plus 1% chlorhexidine varnish monthly application
Number of subjects: 81
Study 30194737 — intervention group
Group type: COMPARATOR
Intervention: Current oral hygiene practice (control)
Number of subjects: 81
Study 26769910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Detective (MoDD)
Number of subjects: 15
Study 24650843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile technology intervention (n=26)
Number of subjects: 51
Study 24650843 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=25)
Number of subjects: 51
Study 22739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (n = 10)
Number of subjects: 26
Study 22739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity cycling (LIC; n = 10)
Number of subjects: 26
Study 22739325 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (CON; n = 6)
Number of subjects: 26
Study 22739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scale (PS)
Number of subjects: 26
Study 22739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength (ISO)
Number of subjects: 26
Study 22739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic strength (PT)
Number of subjects: 26
Study 18786585 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 + OPV
Number of subjects: 450
Study 18786585 — intervention group
Group type: COMPARATOR
Intervention: Placebo + OPV
Number of subjects: 450
Study 18786585 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 450
Study 18947472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus prednisone
Number of subjects: 142
Study 18947472 — intervention group
Group type: COMPARATOR
Intervention: Control (pulse intravenous infusion of cyclophosphamide (CTX) plus prednisone)
Number of subjects: 142
Study 18947472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 142
Study 18947472 — intervention group
Group type: COMPARATOR
Intervention: Control (pulse intravenous infusion of cyclophosphamide (CTX))
Number of subjects: 142
Study 15900990 — intervention group
Group type: EXPERIMENTAL
Intervention: MyStudentBody.com: Alcohol (MSB:Alcohol)
Number of subjects: 0
Study 15900990 — intervention group
Group type: COMPARATOR
Intervention: Control alcohol education Web site
Number of subjects: 0
Study 12598347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone (160 mg day 1, then 20 mg/day for 5 years)
Number of subjects: 474
Study 12598347 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus tamoxifen (20 mg/day for 5 years)
Number of subjects: 474
Study 12598347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 474
Study 12598347 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus tamoxifen
Number of subjects: 474
Study 11091983 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8633818 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions per week for 24 weeks)
Number of subjects: 40
Study 8633818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 1515385 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms epinephrine
Number of subjects: 69
Study 1515385 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms epinephrine
Number of subjects: 69
Study 1515385 — intervention group
Group type: COMPARATOR
Intervention: No epinephrine (Control)
Number of subjects: 69
Study 1515385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients weighing more than 90.8 kg
Number of subjects: 69
Study 1515385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients weighing less than 90.8 kg
Number of subjects: 69
Study 1515385 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms epinephrine (subset)
Number of subjects: 69
Study 1515385 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms epinephrine (subset)
Number of subjects: 69
Study 3975326 — intervention group
Group type: EXPERIMENTAL
Intervention: Women informed of the interest in menstrual cycle symptomatology
Number of subjects: 27
Study 3975326 — intervention group
Group type: COMPARATOR
Intervention: Women and men not informed of the interest in menstrual cycle symptoms
Number of subjects: 27
Study 30688410 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial metformin administration (500-1,000 mg)
Number of subjects: 11
Study 30688410 — intervention group
Group type: COMPARATOR
Intervention: Postprandial metformin administration (500-1,000 mg)
Number of subjects: 11
Study 29430940 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tubes with handles group (ETG)
Number of subjects: 63
Study 29430940 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional elastic bands group (EG)
Number of subjects: 63
Study 29430940 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63
Study 29430940 — intervention group
Group type: COMPARATOR
Intervention: ETG vs CG
Number of subjects: 63
Study 26682789 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) ON
Number of subjects: 66
Study 26682789 — intervention group
Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS) OFF
Number of subjects: 66
Study 25064164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose administered every 6 hours until delivery
Number of subjects: 11
Study 25064164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose
Number of subjects: 11
Study 25064164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 12.5-25 mg/kg/dose administered every 12 hours for 5 doses
Number of subjects: 11
Study 25064164 — intervention group
Group type: COMPARATOR
Intervention: Saline administered within 4 hours of CA diagnosis
Number of subjects: 11
Study 22633469 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D brachytherapy (BT)
Number of subjects: 705
Study 22633469 — intervention group
Group type: COMPARATOR
Intervention: 2D brachytherapy (BT)
Number of subjects: 705
Study 20878879 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release carbamazepine products
Number of subjects: 0
Study 20878879 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated saliva samples (chewing on parafilm wax and spitting method)
Number of subjects: 0
Study 20878879 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dissolution testing with 1% sodium lauryl sulphate
Number of subjects: 0
Study 17593161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 12 weeks
Number of subjects: 157
Study 17593161 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 157
Study 16203960 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus abstinence-based incentives for 12 weeks
Number of subjects: 415
Study 16203960 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 11943936 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (300 microg nasal inhalation)
Number of subjects: 0
Study 11943936 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (combined with tranexamic acid)
Number of subjects: 0
Study 11943936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9951357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive acupuncture treatment (25 sessions over 2 months, 30 minutes each)
Number of subjects: 54
Study 9951357 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 54
Study 7844609 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 beta (0.005 to 0.2 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Number of subjects: 20
Study 7844609 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 beta (0.005 to 0.05 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Number of subjects: 20
Study 7844609 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 beta (0.1 to 0.2 micrograms/kg/d) combined with IL-2 (0.1 mg/m2/d)
Number of subjects: 20
Study 2309545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 96
Study 2309545 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (75 mg)
Number of subjects: 96
Study 393363 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 300 mg
Number of subjects: 241
Study 393363 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g and probenecid 1 g
Number of subjects: 241
Study 31770617 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment with rifapentine and isoniazid
Number of subjects: 513
Study 31770617 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 513
Study 30793411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 81
Study 30793411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 81
Study 30793411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29324935 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network classifier using 123I-FP-CIT brain SPET data (CIT)
Number of subjects: 187
Study 29324935 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT decision rule for right putamen uptake
Number of subjects: 187
Study 29324935 — intervention group
Group type: EXPERIMENTAL
Intervention: Further analysis for patients with right putamen values ≥2.32
Number of subjects: 187
Study 25764229 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personalized report containing information on all nine diabetes care processes
Number of subjects: 14559
Study 25764229 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 14559
Study 23499158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 mg + peginterferon + ribavirin
Number of subjects: 147
Study 23499158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg + peginterferon + ribavirin
Number of subjects: 147
Study 23499158 — intervention group
Group type: COMPARATOR
Intervention: Placebo + peginterferon + ribavirin
Number of subjects: 147
Study 23499158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg + peginterferon + ribavirin (cohort B)
Number of subjects: 147
Study 21196616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral spatulation ≥ 10 mm (group 2)
Number of subjects: 170
Study 21196616 — intervention group
Group type: COMPARATOR
Intervention: Ureteral spatulation ≤ 10 mm (group 1)
Number of subjects: 170
Study 21196616 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy (PCN) and balloon dilatation for ureteral stenosis
Number of subjects: 170
Study 19585548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) (28-30 mg/kg/day)
Number of subjects: 150
Study 19585548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19585548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA)
Number of subjects: 150
Study 17919823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine monotherapy
Number of subjects: 7135
Study 17919823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine with interferons
Number of subjects: 7135
Study 17919823 — intervention group
Group type: COMPARATOR
Intervention: Other treatments (alone or in combination)
Number of subjects: 7135
Study 15372386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 20 mL of 0.9% NaCl solution (5 mL of solution per point) 10 minutes before the operation (Group M)
Number of subjects: 150
Study 15372386 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine (Group B)
Number of subjects: 150
Study 15372386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 20 mL of 0.25% bupivacaine (Group M+B)
Number of subjects: 150
Study 15372386 — intervention group
Group type: COMPARATOR
Intervention: 20 mL 0.9% NaCl (Group S)
Number of subjects: 150
Study 15372386 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of 0.9% NaCl with 2 mg of subcutaneous morphine 10 minutes before surgery (Group S+M)
Number of subjects: 150
Study 11519927 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic causal uncertainty beliefs
Number of subjects: 0
Study 11519927 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated accuracy goal
Number of subjects: 0
Study 11519927 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed causal uncertainty beliefs
Number of subjects: 0
Study 9605677 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 12
Study 9605677 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 12
Study 8169104 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program plus dissection
Number of subjects: 175
Study 8169104 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program alone
Number of subjects: 175